Johnson & Johnson (NY:JNJ)

256.03 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings ↗

October 15, 2025

Via Benzinga

Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions

October 15, 2025

Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which...

Via MarketMinute

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst ↗

October 15, 2025

Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing fair valuation.

Via Benzinga

2 Dividend Stocks I'm Very Thankful I Owned This Year ↗

October 15, 2025

I don't intend to sell my shares of these companies anytime soon.

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Johnson & Johnson To Separate Its Orthopedic Business ↗

October 14, 2025

Via Stocktwits

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗

October 14, 2025

Via Stocktwits

Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off ↗

October 15, 2025

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

Via MarketBeat

New Jersey Rep. Thomas Kean Sold Up to $215K Worth of Franklin Resources Stock ↗

October 15, 2025

Via Benzinga

2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 41% in 12 Months, According to Select Wall Street Analysts ↗

October 15, 2025

Juicy dividends are only part of the attraction with these beaten-down stocks.

Via The Motley Fool

Topics Government

This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy ↗

October 15, 2025

Johnson & Johnson has a very healthy financial profile and growth prospects.

Via The Motley Fool

Topics Bonds

Powell Calms the Markets While Trade Tensions Keep Investors on Edge ↗

October 15, 2025

A dovish tone from Fed Chair Jerome Powell helped Wall Street recover from early losses, but U.S.–China tensions under President Trump’s renewed tariff threats kept sentiment fragile. Strong bank...

Via Chartmill

Topics Economy Government World Trade

AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals

October 14, 2025

A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Looking At Johnson & Johnson's Recent Unusual Options Activity ↗

October 14, 2025

Via Benzinga

The Gathering Storm: AI Overbuilding, Trade Wars, and National Debt Fuel Market Crash Fears

October 14, 2025

As of October 14, 2025, a palpable sense of unease permeates global financial markets, with a growing chorus of analysts and institutions warning of a potential market crash. The prevailing sentiment...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Johnson & Johnson To Spin Off Orthopedics Unit After Raising 2025 Sales Forecast ↗

October 14, 2025

Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings.

Via Talk Markets

S&P Drug Titan J&J Dips After Announcing A Surprise Spinoff ↗

October 14, 2025

The news comes alongside a third-quarter beat and sales guidance hike.

Via Investor's Business Daily

Topics Stocks

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗

October 14, 2025

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Via Benzinga

Johnson & Johnson (NYSE:JNJ) Beats Q3 2025 Estimates and Raises Full-Year Sales Outlook ↗

October 14, 2025

Johnson & Johnson (JNJ) beat Q3 2025 earnings estimates, raised its full-year sales outlook, and announced a planned spin-off of its Orthopedics business.

Via Chartmill

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

October 14, 2025

From Johnson & Johnson

Via Business Wire

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

October 14, 2025

From Johnson & Johnson

Via Business Wire

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

October 14, 2025

From Johnson & Johnson

Via Business Wire

Stock Market Today: S&P 500, Nasdaq Futures Tumble Ahead Of Big Bank Earnings—Goldman Sachs, JPMorgan, Citigroup In Focus ↗

October 14, 2025

U.S. stock futures declined on Tuesday following Monday’s reversal rally. Futures of major benchmark indices were lower.

Via Benzinga

Topics Stocks

Earnings Scheduled For October 14, 2025 ↗

October 14, 2025

Via Benzinga

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗

October 14, 2025

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Via Stocktwits

Topics Government World Trade

Goldman Sachs, JPMorgan Chase And 3 Stocks To Watch Heading Into Tuesday ↗

October 14, 2025

US stock futures lower, focus on Goldman Sachs, JPMorgan, Polaris, Johnson & Johnson, and Citigroup earnings.

Via Benzinga

Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing ↗

October 13, 2025

Via The Motley Fool

Topics Regulatory Compliance

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside ↗

October 13, 2025

Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035.

Via Benzinga

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗

October 13, 2025

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

Via Benzinga

Dividend Powerhouses: Should You Grab These 3 Before Earnings Drop?

October 13, 2025

As the Q3 2025 earnings season hits full stride, a critical question looms for income-focused investors: are "dividend powerhouses" still a safe haven, and should they be considered before their...

Via MarketMinute

Topics Bonds Earnings Economy

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗

October 13, 2025

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.